Other
Neoplasm by Special Category
CI-CAN-00000004Explore in graph →
Non-malignant21,340 active trials259 approved drugs3,859 evidence items
- NCIt
- C7062
Loading cancer entity…
Loading cancer entity…
Other
CI-CAN-00000004Explore in graph →
Clinical trials
95,701 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07645625 | Pembrolizumab Registry for Outcomes and Treatment Evaluation in Cervical Cancer(PROTECx) | recruiting | Phase 4 | 261 | University Medical Center GroningenOTHER | 1 | Jun 29, 2026 | clinicaltrials |
| NCT06016855 | Surgical Debulking Prior to Peptide Receptor Radionuclide Therapy in Well Differentiated Gastroenteropancreatic Neuroendocrine Tumors | recruiting | Phase 4 | 6 | Vanderbilt-Ingram Cancer CenterOTHER | 1 | Jun 24, 2026 |
| clinicaltrials |
| NCT07209787 | SIS-Reinforced vs. Conventional Anastomosis for Mid-to-Low Rectal Cancer: A Multicenter RCT on Anastomotic Leak | recruiting | Phase 4 | 966 | Beijing Chao Yang HospitalOTHER | 1 | Jun 17, 2026 | clinicaltrials |
| NCT07600580 | The Association Between Bilateral Intermediate Cervical Plexus Block During Total Thyroidectomy and Surgical Stress Response | recruiting | Phase 4 | 48 | University Hospital DubravaOTHER | 1 | Jun 16, 2026 | clinicaltrials |
| NCT07405086 | Morning Versus Afternoon Administration of Immunotherapy for the Treatment of Advanced or Metastatic Solid Tumors, The Knight SHIFT Study | recruiting | Phase 4 | 160 | OHSU Knight Cancer InstituteOTHER | 1 | Jun 12, 2026 | clinicaltrials |
| NCT06162377 | Methylnatrexone In Resectable Head and Neck Squamous Cell Carcinoma (MINK). A "Window of Opportunity" Pilot Study. | recruiting | Phase 4 | 25 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 10, 2026 | clinicaltrials |
| NCT05803941 | Long-Term Safety of Lutetium (177Lu) Vipivotide Tetraxetan in Participants With Prostate Cancer | recruiting | Phase 4 | 700 | Novartis PharmaceuticalsINDUSTRY | 11 | Jun 4, 2026 | clinicaltrials |
| NCT07286188 | Effect of Misoprostol on Fluid Deficit Volume in Hysteroscopic Myomectomy | recruiting | Phase 4 | 40 | Northwestern UniversityOTHER | 1 | Jun 1, 2026 | clinicaltrials |
| NCT04460235 | Clinical Trial Assessing the Immunogenicity of an Anti-pneumococcal Vaccination Strategy (PCV13+PPV23 Versus PREVENAR20) in Adult Patients Treated for a Lymphoma(HEMATOVAC) | recruiting | Phase 4 | 160 | Poitiers University HospitalOTHER | 1 | May 29, 2026 | clinicaltrials |
| NCT06370000 | Oral Azacitidine in Transplant-Eligible Patients With Acute Myeloid Leukemia (AML) Suffering From Health-Inequality(REMAIN1) | recruiting | Phase 4 | 12 | Virginia Commonwealth UniversityOTHER | 1 | May 29, 2026 | clinicaltrials |
| NCT04921137 | Evaluating Harms and Benefits of Endocrine Therapy in Patients ≥70 Years of Age With Lower Risk Breast Cancer | recruiting | Phase 4 | 500 | Ottawa Hospital Research InstituteOTHER | 1 | May 28, 2026 | clinicaltrials |
| NCT04265430 | Serial Magnetic Resonance Imaging for the Prediction of Radiation-Induced Changes in Normal Tissue of Patients With Oral Cavity or Skull Base Tumors | recruiting | Phase 4 | 425 | M.D. Anderson Cancer CenterOTHER | 1 | May 22, 2026 | clinicaltrials |
| NCT06733350 | Testosterone Replacement Therapy for the Treatment of Low Testosterone in Hypogonadal Men With Localized Prostate Cancer on Active Surveillance | recruiting | Phase 4 | 600 | Roswell Park Cancer InstituteOTHER | 1 | May 14, 2026 | clinicaltrials |
| NCT07150624 | The Treatment of Liver Injury After Liver Resection With Polyene Phosphatidylcholine | recruiting | Phase 4 | 96 | Anhui Provincial HospitalOTHER_GOV | 1 | May 11, 2026 | clinicaltrials |
| NCT04604509 | Nicotine Replacement Therapy, Counseling, Varenicline, and Bupropion for Smoking Cessation, the PISCES I Trial | recruiting | Phase 4 | 2,010 | M.D. Anderson Cancer CenterOTHER | 1 | May 4, 2026 | clinicaltrials |
| NCT07561892 | Study of the Effectiveness and Safety of Daunorubicin /Idarubicin ± Silibinin in Treating Newly Diagnosed AML (Non-M3).(AML) | recruiting | Phase 4 | 100 | Fujian Medical University Union HospitalOTHER | 1 | May 1, 2026 | clinicaltrials |
| NCT05726136 | Fluid Challenge and Plasma Volume, During Surgery(FC-VE) | recruiting | Phase 4 | 60 | Joachim ZdolsekOTHER | 1 | Apr 30, 2026 | clinicaltrials |
| NCT06646471 | PROspective Master-protocol for Evaluation of Systemic THErapeutics in Elderly With Thoracic Malignancies(PROMETHEE) | recruiting | Phase 4 | 500 | GFPC InvestigationOTHER | 1 | Apr 29, 2026 | clinicaltrials |
| NCT06330038 | Anesthesia and Non-small Cell Lung Cancer Recurrence(GASTIVA) | recruiting | Phase 4 | 5,384 | Samsung Medical CenterOTHER | 1 | Apr 20, 2026 | clinicaltrials |
| NCT05203172 | The FLOTILLA Study: Providing Continued Access to The Study Medicines Encorafenib and Binimetinib for Participants in Prior Clinical Trials | recruiting | Phase 4 | 46 | PfizerINDUSTRY | 17 | Apr 7, 2026 | clinicaltrials |
| NCT07474519 | Studying the Relationship of Patient Positioning and Intravesical Bacillus Calmette Guerin Dwell Time to Improve the Treatment of Non-muscle Invasive Bladder Cancer | recruiting | Phase 4 | 40 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Mar 16, 2026 | clinicaltrials |
| NCT06525740 | Methadone Versus Intrathecal Hydromorphone for Postoperative Pain Relief in Gynecologic Cancer Undergoing Surgery | recruiting | Phase 4 | 140 | Mayo ClinicOTHER | 1 | Mar 4, 2026 | clinicaltrials |
| NCT06876649 | A Master Protocol to Evaluate the Long-Term Safety of (LY3527727) Pirtobrutinib | recruiting | Phase 4 | 787 | Eli Lilly and CompanyINDUSTRY | 8 | Mar 2, 2026 | clinicaltrials |
| NCT06876662 | A Study of (LY3527727) Pirtobrutinib in Participants With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma | recruiting | Phase 4 | 279 | Eli Lilly and CompanyINDUSTRY | 8 | Mar 2, 2026 | clinicaltrials |
| NCT05521789 | Erector Spinae Block for Thoracic Surgery | recruiting | Phase 4 | 70 | George Washington UniversityOTHER | 1 | Feb 25, 2026 | clinicaltrials |
| NCT06831370 | A Study of Brentuximab Vedotin With Doxorubicin, Vinblastine and Dacarbazine in Adults With Hodgkin Lymphoma in India | recruiting | Phase 4 | 124 | TakedaINDUSTRY | 1 | Feb 23, 2026 | clinicaltrials |
| NCT06764095 | Enfortumab Vedotin and Pembrolizumab With Cystectomy and/or Ureterectomy for Locally Advanced or Metastatic Bladder and Upper Urothelial Tract Cancer, CAST-AI Trial | recruiting | Phase 4 | 75 | Mayo ClinicOTHER | 1 | Feb 12, 2026 | clinicaltrials |
| NCT06748001 | Avapritinib Rollover Study | recruiting | Phase 4 | 60 | Blueprint Medicines CorporationINDUSTRY | 6 | Feb 9, 2026 | clinicaltrials |
| NCT07042581 | A Study of Revaree Plus in People With Breast Cancer | recruiting | Phase 4 | 60 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Feb 6, 2026 | clinicaltrials |
| NCT06105801 | EBUS-TBNA vs Transbronchial Mediastinal Cryobiopsy for Adequacy of Next Generation Sequencing(FROSTBITE-3) | recruiting | Phase 4 | 250 | Vanderbilt-Ingram Cancer CenterOTHER | 1 | Feb 2, 2026 | clinicaltrials |
| NCT06099093 | Pilot of 18F-DCFPyL-PSMA PET in mCRPC Patients Receiving 117Lu-Vipivotide Tetraxetan | recruiting | Phase 4 | 30 | Brigham and Women's HospitalOTHER | 1 | Jan 29, 2026 | clinicaltrials |
| NCT07355699 | Application of Orelabrutinib With or Without CD20 Monoclonal Antibody in Previously Untreated Marginal Zone Lymphoma | recruiting | Phase 4 | 88 | Beijing Tongren HospitalOTHER | 1 | Jan 21, 2026 | clinicaltrials |
| NCT07320105 | Postoperative Radiotherapy for Postoperative N2 Metastases of NSCLC in the Immunotherapy Era (Phase II) | recruiting | Phase 4 | 60 | Fujian Cancer HospitalOTHER_GOV | 1 | Jan 6, 2026 | clinicaltrials |
| NCT05722405 | Ixazomib Plus Low-dose Lenalidomide Versus Ixazomib Alone for Maintenance Treatment of High Risk Multiple Myeloma | recruiting | Phase 4 | 100 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Jan 5, 2026 | clinicaltrials |
| NCT07315828 | Accuracy of Indocyanine Green (ICG) Fluorescence Imaging in Giant Cell Tumor of Bone Surgery(ICG-GCTB) | recruiting | Phase 4 | 40 | Shanghai Jiao Tong University Affiliated Sixth People's HospitalOTHER | 1 | Jan 5, 2026 | clinicaltrials |
| NCT07315841 | Accuracy of Indocyanine Green (ICG) Fluorescence Imaging in Tenosynovial Giant Cell Tumor Surgery(ICG-TGCT) | recruiting | Phase 4 | 40 | Shanghai Jiao Tong University Affiliated Sixth People's HospitalOTHER | 1 | Jan 5, 2026 | clinicaltrials |
| NCT05962541 | Vesical Imaging-Reporting and Data System (VI-RADS) Followed by Photodynamic Trans-urethral Resection of Bladder Tumours (PDD-TURBT) to Avoid Secondary Resections (Re-TURBT) in Non-Muscle Invasive Bladder Cancers (NMIBCs)(CUT-less) | recruiting | Phase 4 | 327 | University of Roma La SapienzaOTHER | 1 | Dec 31, 2025 | clinicaltrials |
| NCT07308717 | Gabapentin And Breast Surgery Decision Architecture Randomization Trial (GABS-DART) Protocol | recruiting | Phase 4 | 1,896 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Dec 30, 2025 | clinicaltrials |
| NCT07262957 | Preventing Postoperative Complications in Patients Undergoing High-risk Pancreatoduodenectomy With a Bundle Approach Including Hydrocortisone, Octreotide, and the Teres Ligament Patch (PANENCA)(PANENCA) | recruiting | Phase 4 | 400 | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)OTHER | 1 | Dec 22, 2025 | clinicaltrials |
| NCT07272512 | Prospective Multicenter Real-world Study of Surufatinib in Patients With Advanced Neuroendocrine Neoplasms(ZSPAC-17) | recruiting | Phase 4 | 350 | Shanghai Zhongshan HospitalOTHER | 1 | Dec 19, 2025 | clinicaltrials |
| NCT06717919 | HOPE Against Cancer Recurrence in HCC(HOPE4Cancer) | recruiting | Phase 4 | 220 | Philipp DutkowskiOTHER | 17 | Dec 16, 2025 | clinicaltrials |
| NCT07200544 | Meloxicam in Mohs Micrographic Surgery | recruiting | Phase 4 | 300 | University of OklahomaOTHER | 1 | Dec 15, 2025 | clinicaltrials |
| NCT05525767 | Chemotherapy Combined With Bevacizumab Neoadjuvant Therapy for HER2-negative Breast Cancer | recruiting | Phase 4 | 75 | Hebei Medical University Fourth HospitalOTHER | 1 | Dec 11, 2025 | clinicaltrials |
| NCT06251076 | Plan Development for Giving Teclistamab in the Outpatient Setting | recruiting | Phase 4 | 15 | University Health Network, TorontoOTHER | 1 | Dec 10, 2025 | clinicaltrials |
| NCT07270835 | Zanubrutinib Combined With Rituximab in the Treatment of Secondary HLH in B-cell Lymphoma | recruiting | Phase 4 | 40 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Dec 8, 2025 | clinicaltrials |
| NCT07139366 | Saccharomyces Boulardii Combined With Bismuth Quadruple Therapy for Helicobacter Pylori Rescue Treatment | recruiting | Phase 4 | 1,248 | Yongquan ShiOTHER | 1 | Dec 2, 2025 | clinicaltrials |
| NCT06072807 | Brain [18F]-FES PET/CT in Patients With Estrogen-Receptor Positive Breast Cancer | recruiting | Phase 4 | 20 | Weill Medical College of Cornell UniversityOTHER | 1 | Nov 24, 2025 | clinicaltrials |
| NCT04081701 | 68-Ga DOTATATE PET/MRI in the Diagnosis and Management of Somatostatin Receptor Positive CNS Tumors.(DOMINO-START) | recruiting | Phase 4 | 200 | Weill Medical College of Cornell UniversityOTHER | 1 | Nov 21, 2025 | clinicaltrials |
| NCT06574022 | Post-mastectomy Recovery: Comparing Preoperative PECS-II Blocks With Intraoperative Pectoral Blocks | recruiting | Phase 4 | 100 | University of CincinnatiOTHER | 1 | Nov 4, 2025 | clinicaltrials |
Data updated 22 days agoSource updated Jun 29, 2026source: clinicaltrials